1. Home
  2. JANX vs CRTO Comparison

JANX vs CRTO Comparison

Compare JANX & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$16.07

Market Cap

984.3M

Sector

Health Care

ML Signal

HOLD

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$22.33

Market Cap

874.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
JANX
CRTO
Founded
2017
2005
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
984.3M
874.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
JANX
CRTO
Price
$16.07
$22.33
Analyst Decision
Buy
Strong Buy
Analyst Count
13
10
Target Price
$47.00
$34.00
AVG Volume (30 Days)
1.5M
498.2K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.95
EPS
N/A
0.15
Revenue
$10,000,000.00
$2,296,692,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.54
P/E Ratio
N/A
$152.73
Revenue Growth
N/A
27.65
52 Week Low
$12.12
$15.58
52 Week High
$35.34
$26.40

Technical Indicators

Market Signals
Indicator
JANX
CRTO
Relative Strength Index (RSI) 59.91 62.43
Support Level $13.21 $18.83
Resistance Level $16.75 $23.28
Average True Range (ATR) 0.66 1.23
MACD 0.01 0.15
Stochastic Oscillator 65.43 62.31

Price Performance

Historical Comparison
JANX
CRTO

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.

Share on Social Networks: